Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development

被引:12
作者
Shashidharamurthy, Rangaiah [1 ]
Bozeman, Erica N. [1 ]
Patel, Jaina [1 ]
Kaur, Ramneet [1 ]
Meganathan, Jeyandra [1 ]
Selvaraj, Periasamy [1 ]
机构
[1] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
关键词
cancer vaccine; cancer immunotherapy; protein transfer; glycosylphosphatidylinositol (GPI); cytokines; immunostimulatory molecules; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; ANTIBODY-CALICHEAMICIN CONJUGATE; ANTI-CD20; MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; GLYCOLIPID-ANCHORED IL-12; TUMOR-SPECIFIC IMMUNITY; ACUTE MYELOID-LEUKEMIA; PHASE-II TRIAL; GENE-TRANSFER;
D O I
10.1002/med.20237
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cancer cells have developed numerous ways to escape immune surveillance and gain unlimited proliferative capacity. Currently, several chemotherapeutic agents and radiotherapy, either alone or in combination, are being used to treat malignancies. However, both of these therapies are associated with several limitations and detrimental side effects. Therefore, recent scientific investigations suggest that immunotherapy is among the most promising new approaches in modern cancer therapy. The focus of cancer immunotherapy is to boost both acquired and innate immunity against malignancies by specifically targeting tumor cells, and leaving healthy cells and tissues unharmed. Cellular, cytokine, gene, and monoclonal antibody therapies have progressively become promising immunotherapeutic approaches that are being tested for several cancers in preclinical models as well as in the clinic. In this review, we discuss recent advances in these immunotherapeutic approaches, focusing on new strategies that allow the expression of specific immunostimulatory molecules on the surface of tumor cells to induce robust antitumor immunity.
引用
收藏
页码:1197 / 1219
页数:23
相关论文
共 170 条
  • [1] Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma
    Amato, Robert J.
    Malya, Rahul
    Rawat, Anish
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (03): : 237 - 243
  • [2] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Ansell, SM
    Witzig, TE
    Kurtin, PJ
    Sloan, JA
    Jelinek, DF
    Howell, KG
    Markovic, SN
    Habermann, TM
    Klee, GG
    Atherton, PJ
    Erlichman, C
    [J]. BLOOD, 2002, 99 (01) : 67 - 74
  • [3] Current status of immunological therapies for prostate cancer
    Antonarakis, Emmanuel S.
    Drake, Charles G.
    [J]. CURRENT OPINION IN UROLOGY, 2010, 20 (03) : 241 - 246
  • [4] Araki A, 2004, INT J MOL MED, V14, P571
  • [5] Baselga J, 2001, EUR J CANCER, V37, pS16
  • [6] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
  • [7] CONSTITUTIVE EXPRESSION OF B7 RESTORES IMMUNOGENICITY OF TUMOR-CELLS EXPRESSING TRUNCATED MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULES
    BASKAR, S
    OSTRANDROSENBERG, S
    NABAVI, N
    NADLER, LM
    FREEMAN, GJ
    GLIMCHER, LH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) : 5687 - 5690
  • [8] Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
    Beers, Stephen A.
    French, Ruth R.
    Chan, H. T. Claude
    Lim, Sean H.
    Jarrett, Timothy C.
    Vidal, Regina Mora
    Wijayaweera, Sahan S.
    Dixon, Sandra V.
    Kim, Hyungjin
    Cox, Kerry L.
    Kerr, Jonathan P.
    Johnston, David A.
    Johnson, Peter W. M.
    Verbeek, J. Sjef
    Glennie, Martin J.
    Cragg, Mark S.
    [J]. BLOOD, 2010, 115 (25) : 5191 - 5201
  • [9] The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
    Beum, PV
    Kennedy, AD
    Williams, ME
    Lindorfer, MA
    Taylor, RP
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 176 (04) : 2600 - 2609
  • [10] Billadeau DD, 2002, J CLIN INVEST, V109, P161, DOI 10.1172/JCI14843